CNTA PE Ratio & Valuation,Is CNTA Overvalued

CNTA Relative Valuation

CNTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNTA is overvalued; if below, it's undervalued.

Historical Valuation

Centessa Pharmaceuticals PLC (CNTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.15. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：25.72

Fair

-15.86

-14.00

EV/EBITDA

Centessa Pharmaceuticals PLC. (CNTA) has a current EV/EBITDA of -14.00. The 5-year average EV/EBITDA is -4.55. The thresholds are as follows: Strongly Undervalued below -12.73, Undervalued between -12.73 and -8.64, Fairly Valued between -0.46 and -8.64, Overvalued between -0.46 and 3.63, and Strongly Overvalued above 3.63. The current Forward EV/EBITDA of -14.00 falls within the Strongly Undervalued range.

-15.53

EV/EBIT

Centessa Pharmaceuticals PLC. (CNTA) has a current EV/EBIT of -15.53. The 5-year average EV/EBIT is -4.37. The thresholds are as follows: Strongly Undervalued below -12.54, Undervalued between -12.54 and -8.46, Fairly Valued between -0.28 and -8.46, Overvalued between -0.28 and 3.80, and Strongly Overvalued above 3.80. The current Forward EV/EBIT of -15.53 falls within the Strongly Undervalued range.

4980.29

Centessa Pharmaceuticals PLC. (CNTA) has a current PS of 4980.29. The 5-year average PS is 208.56. The thresholds are as follows: Strongly Undervalued below -1688.72, Undervalued between -1688.72 and -740.08, Fairly Valued between 1157.20 and -740.08, Overvalued between 1157.20 and 2105.84, and Strongly Overvalued above 2105.84. The current Forward PS of 4980.29 falls within the Strongly Overvalued range.

-24.85

P/OCF

Centessa Pharmaceuticals PLC. (CNTA) has a current P/OCF of -24.85. The 5-year average P/OCF is -8.93. The thresholds are as follows: Strongly Undervalued below -30.21, Undervalued between -30.21 and -19.57, Fairly Valued between 1.71 and -19.57, Overvalued between 1.71 and 12.35, and Strongly Overvalued above 12.35. The current Forward P/OCF of -24.85 falls within the Undervalued range.

-21.85

P/FCF

Centessa Pharmaceuticals PLC. (CNTA) has a current P/FCF of -21.85. The 5-year average P/FCF is -5.36. The thresholds are as follows: Strongly Undervalued below -17.37, Undervalued between -17.37 and -11.37, Fairly Valued between 0.64 and -11.37, Overvalued between 0.64 and 6.64, and Strongly Overvalued above 6.64. The current Forward P/FCF of -21.85 falls within the Strongly Undervalued range.

Centessa Pharmaceuticals PLC (CNTA) has a current Price-to-Book (P/B) ratio of 11.46. Compared to its 3-year average P/B ratio of 4.29 , the current P/B ratio is approximately 167.21% higher. Relative to its 5-year average P/B ratio of 4.09, the current P/B ratio is about 180.40% higher. Centessa Pharmaceuticals PLC (CNTA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -20.16%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -21.88% , the current FCF yield is about -100.00% lower.

11.46

P/B

Median3y

4.29

Median5y

4.09

-4.74

FCF Yield

Median3y

-20.16

Median5y

-21.88

Competitors Valuation Multiple

The average P/S ratio for CNTA's competitors is 0.00, providing a benchmark for relative valuation. Centessa Pharmaceuticals PLC Corp (CNTA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CNTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CNTA in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Centessa Pharmaceuticals PLC (CNTA) currently overvalued or undervalued?

What is Centessa Pharmaceuticals PLC (CNTA) fair value?

CNTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between to according to relative valuation methord.

How does CNTA's valuation metrics compare to the industry average?

What is the current P/B ratio for Centessa Pharmaceuticals PLC (CNTA) as of Dec 17 2025?

As of Dec 17 2025, Centessa Pharmaceuticals PLC (CNTA) has a P/B ratio of 11.46. This indicates that the market values CNTA at 11.46 times its book value.

What is the current FCF Yield for Centessa Pharmaceuticals PLC (CNTA) as of Dec 17 2025?

As of Dec 17 2025, Centessa Pharmaceuticals PLC (CNTA) has a FCF Yield of 0.00%. This means that for every dollar of Centessa Pharmaceuticals PLC’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA) as of Dec 17 2025?

As of Dec 17 2025, Centessa Pharmaceuticals PLC (CNTA) has a Forward P/E ratio of -15.86. This means the market is willing to pay $-15.86 for every dollar of Centessa Pharmaceuticals PLC’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Centessa Pharmaceuticals PLC (CNTA) as of Dec 17 2025?

As of Dec 17 2025, Centessa Pharmaceuticals PLC (CNTA) has a Forward P/S ratio of 0.00. This means the market is valuing CNTA at $0.00 for every dollar of expected revenue over the next 12 months.

CNTA Valuation